EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients
Uložené v:
| Názov: | EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients |
|---|---|
| Autori: | Cornberg, Markus, Buti, Maria, Eberhardt, Christiane S., Grossi, Paolo Antonio, Shouval, Daniel |
| Prispievatelia: | CiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover. |
| Zdroj: | J Hepatol Journal of hepatology Netherlands Journal of Hepatology |
| Informácie o vydavateľovi: | Elsevier BV, 2021. |
| Rok vydania: | 2021 |
| Predmety: | 0301 basic medicine, COVID-19 Vaccines, 616.07, COVID-19 / epidemiology, Immunocompromised Host, 03 medical and health sciences, Humans, Vaccination / methods, Liver Diseases / epidemiology, COVID-19 Vaccines / pharmacology, 0303 health sciences, Liver transplantation, Hepatology, SARS-CoV-2, Liver Diseases, Vaccination, COVID-19 / prevention & control, COVID-19, Liver Diseases / therapy, Liver Transplantation / statistics & numerical data, Influenza, Liver Transplantation, 3. Good health, Liver Transplantation / methods, Biliary Tract Neoplasms / therapy, Biliary Tract Neoplasms, Cirrhosis, Risk Adjustment, Biliary Tract Neoplasms / epidemiology, Position Paper, Vaccine, Liver Diseases / immunology |
| Popis: | According to a recent World Health Organization estimate, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which originated in China in 2019, has spread globally, infecting nearly 100 million people worldwide by January 2021. Patients with chronic liver diseases (CLD), particularly cirrhosis, hepatobiliary malignancies, candidates for liver transplantation, and immunosuppressed individuals after liver transplantation appear to be at increased risk of infections in general, which in turn translates into increased mortality. This is also the case for SARS-CoV-2 infection, where patients with cirrhosis, in particular, are at high risk of a severe COVID-19 course. Therefore, vaccination against various pathogens including SARS-CoV-2, administered as early as possible in patients with CLD, is an important protective measure. However, due to impaired immune responses in these patients, the immediate and long-term protective response through immunisation may be incomplete. The current SARS-CoV-2 pandemic has led to the exceptionally fast development of several vaccine candidates. A small number of these SARS-CoV-2 vaccine candidates have already undergone phase III, placebo-controlled, clinical trials in healthy individuals with proof of short-term safety, immunogenicity and efficacy. However, although regulatory agencies in the US and Europe have already approved some of these vaccines for clinical use, information on immunogenicity, duration of protection and long-term safety in patients with CLD, cirrhosis, hepatobiliary cancer and liver transplant recipients has yet to be generated. This review summarises the data on vaccine safety, immunogenicity, and efficacy in this patient population in general and discusses the implications of this knowledge on the introduction of the new SARS-CoV-2 vaccines. |
| Druh dokumentu: | Article Other literature type |
| Popis súboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 0168-8278 |
| DOI: | 10.1016/j.jhep.2021.01.032 |
| Prístupová URL adresa: | http://www.journal-of-hepatology.eu/article/S0168827821000817/pdf https://pubmed.ncbi.nlm.nih.gov/33563499 http://hdl.handle.net/10033/622772 https://archive-ouverte.unige.ch/unige:168571 https://doi.org/10.1016/j.jhep.2021.01.032 |
| Rights: | Elsevier TDM CC BY NC ND |
| Prístupové číslo: | edsair.doi.dedup.....a637adf0e0130f0708d1945b2b86abdf |
| Databáza: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | According to a recent World Health Organization estimate, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which originated in China in 2019, has spread globally, infecting nearly 100 million people worldwide by January 2021. Patients with chronic liver diseases (CLD), particularly cirrhosis, hepatobiliary malignancies, candidates for liver transplantation, and immunosuppressed individuals after liver transplantation appear to be at increased risk of infections in general, which in turn translates into increased mortality. This is also the case for SARS-CoV-2 infection, where patients with cirrhosis, in particular, are at high risk of a severe COVID-19 course. Therefore, vaccination against various pathogens including SARS-CoV-2, administered as early as possible in patients with CLD, is an important protective measure. However, due to impaired immune responses in these patients, the immediate and long-term protective response through immunisation may be incomplete. The current SARS-CoV-2 pandemic has led to the exceptionally fast development of several vaccine candidates. A small number of these SARS-CoV-2 vaccine candidates have already undergone phase III, placebo-controlled, clinical trials in healthy individuals with proof of short-term safety, immunogenicity and efficacy. However, although regulatory agencies in the US and Europe have already approved some of these vaccines for clinical use, information on immunogenicity, duration of protection and long-term safety in patients with CLD, cirrhosis, hepatobiliary cancer and liver transplant recipients has yet to be generated. This review summarises the data on vaccine safety, immunogenicity, and efficacy in this patient population in general and discusses the implications of this knowledge on the introduction of the new SARS-CoV-2 vaccines. |
|---|---|
| ISSN: | 01688278 |
| DOI: | 10.1016/j.jhep.2021.01.032 |